ARID1A mutations confer intrinsic and acquired resistance to cetuximab treatment in colorectal cancer
- Citation:
- Nat Commun vol 13 (1) 5478
- Year:
- 2022
- Type:
- Manuscript
- Funding:
- NCTN
- Endpoint:
- Secondary-not-in-original
- Analysis:
- Primary
- Data Sharing:
- Alliance-data-source,-external-user
- Status:
- Presented/Published
- Citation Status:
- epub-ppub
- Note:
- Methodological:
- No
- Biospecimen:
- Yes
- SDC:
- No
- Book Volume:
- Parents:
- 3247
- Children:
- None
- Program:
- TRP
- Primary Committee:
- Correl Sci NOS
- Sec. Committees:
- Pharmas:
- Bristol Myers Squibb (BMS), Genentech, Pfizer, Sanofi
- Grants:
- U10CA180821, U10CA180882, U24CA196171, UG1CA180830, P30CA014089, UG1CA233373, U10CA180888 (SWOG)
- Corr. Author:
- Authors:
- Radia M. Johnson Xueping Qu Chu-Fang Lin Ling-Yuh Huw Avinashnarayan Venkatanarayan Ethan Sokol Fang-Shu Ou Nnamdi Ihuegbu Oliver A. Zill Omar Kabbarah Lisa Wang Richard Bourgon Felipe de Sousa e Melo Chris Bolen Anneleen Daemen Alan P. Venook Federico Innocenti Heinz-Josef Lenz Carlos Bais
- Networks:
- CA011, CA136, LAPS-MN026, LAPS-NC007
- Study
- Alliance-A152108
- Multiple Studies, or Legacy Studies in Alliance Study:
- CALGB-80405
- Phases:
- N/A, 3
- Keywords: